Abstract
Since 1982, four consecutive studies on childhood acute myeloid leukaemia (AML) (namely LAM-82, -87, -87M and -92) have been conducted in Italy by the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) group. The induction therapy of the first three studies consisted of daunorubicin and cytarabine structured in a 3+7 backbone. In the most recent protocol (LAM92), patients received two induction courses including idarubicin, cytarabine and etoposide. Patients with acute promyelocytic leukaemia (20% of diagnoses) were included in LAM-87 and 87M studies. Postremissional therapy significantly changed over time, with an ever-increasing role given to stem cell transplantation (SCT). The long-term outcome of patients enrolled in the LAM-82, 87 and 87M studies was comparable, whereas that of children treated according to LAM-92 study was significantly better (P<0.005). Either allogeneic or autologous SCT was employed as consolidation therapy in more than 75% of cases enrolled in this latter study. Patients enrolled in the LAM-92 study were stratified in standard and high-risk groups with different outcome (67 vs 47%, respectively, P=0.04). Altogether, the results obtained in these four studies have permitted a progressive refinement of treatment, contributing to the structure of the ongoing LAM-2002 protocol that stratifies patients according to the presence of definite genetic anomalies and response to induction therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vormoor J, Boos J, Stahnke K, Jurgens H, Ritter J, Creutzig U . Therapy of childhood acute myelogenous leukemia. Ann Hematol 1996; 73: 11–24.
Amadori S, Giona F, Giuliano M, Moleti ML, Pession A, Rolla M et al. Therapeutic strategies for postremission treatment in childhood acute myeloid leukemia (Aml). The Aieop experience 1987–1991. Leukemia 1992; 6 (Suppl. 2): 44–47.
Pession A, Rondelli R, Haupt R, Magnani C, Pastore G, Terracini B et al. Il sistema di rilevazione dei casi di tumore maligno in età pediatrica in Italia. Riv Ital Pediatr (Ijp) 2000; 26: 333–341.
Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD . Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 1983; 62: 315–319.
Amadori S, Ceci A, Comelli A, Madon E, Masera G, Nespoli L et al. Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204. J Clin Oncol 1987; 5: 1356–1363.
Meloni G, De-Fabritiis P, Petti MC, Mandelli F . BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 1990; 75: 2282–2285.
Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986; 315: 141–147.
Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol 1993; 11: 1046–1054.
Wolff SN, Herzig RH, Phillips GL, Lazarus HM, Greer JP, Stein RS et al. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. Semin Oncol 1987; 14 (Suppl. 1): 12–17.
Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 1989; 7: 1260–1267.
Carella AM, Berman E, Maraone MP, Ganzina F . Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologica 1990; 75: 159–169.
Berman E, McBride M . Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267–3273.
Hollingshead LM, Faulds D . Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 42: 690–719.
Testi AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M et al. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447–453.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med 1985; 103: 620–625.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991; 78: 325–329.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French–American–British Cooperative Group. Ann Intern Med 1985; 103: 460–462.
Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM . High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996; 87: 308–313.
Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia 2001; 15: 348–354.
Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG et al. Randomized comparison of DAT vs ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997; 89: 2311–2318.
Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R et al. Etoposide in acute non-lymphocytic leukemia. Australian Leukemia Study Group. Blood 1990; 75: 27–32.
Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J et al. Autologous bone marrow transplantation vs intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996; 334: 1428–1434.
Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from Children's Cancer Group. Blood 2001; 97: 56–62.
Locatelli F, Labopin M, Ortega J, Meloni G, Dini G, Messina C et al. Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. Blood 2003; 101: 1611–1619.
Gorin NC, Labopin M, Meloni G, Korbling M, Carella A, Herve P et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 1991; 5: 896–904.
Miller CB, Rowlings PA, Zhang MJ, Jones RJ, Piantadosi S, Keating A et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol 2001; 29: 1336–1346.
Stevens RF, Hann IM, Wheatley K, Gray RG . Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 1998; 101: 30–40.
Cesaro S, Meloni G, Messina C, Pillon M, Proglia A, Lanino E et al. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation. Bone Marrow Transplant 2001; 28: 131–136.
Bonetti F, Zecca M, Pession A, Messina C, Montagna D, Lanino E et al. Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. The Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplantation Group. J Clin Oncol 1999; 17: 3729–3735.
Locatelli F, Pession A, Bonetti F, Maserati E, Prete L, Pedrazzoli P et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia 1994; 8: 844–849.
Cassileth PA, Harrigton DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656.
Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of pre-remission and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Group Study. Blood 2000; 96: 4075–4083.
Martinez-Climent JA, Lane NJ, Rubin CM, Morgan E, Johnstone HS, Mick R et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia 1995; 9: 95–101.
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al., on behalf of the Medical Research Concil Adult and Children's Leukemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML10 trial. Blood 1998; 92: 2322–2333.
Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–1021.
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028.
Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood 2001; 97: 3727–3732.
Acknowledgements
Until 2000, the coordinator of the AIEOP studies was professor Franco Mandelli, whom we thank for his valuable contribution to the improvement of results in childhood AML in Italy. We are indebted also with Dr Laura Sainati and Dr Emanuela Frascella who performed most of the cytogenetic and molecular biology evaluation on centralised marrow/blood samples.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Pession, A., Rondelli, R., Basso, G. et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia 19, 2043–2053 (2005). https://doi.org/10.1038/sj.leu.2403869
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403869
Keywords
This article is cited by
-
PCDH17 functions as a common tumor suppressor gene in acute leukemia and its transcriptional downregulation is mediated primarily by aberrant histone acetylation, not DNA methylation
International Journal of Hematology (2020)
-
The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia
Leukemia (2011)
-
MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures
BMC Medical Genomics (2009)
-
‘Allogeneic marrow transplantation in children with acute leukemia: a practice whose time has gone’: twenty years later
Leukemia (2009)
-
Acute myeloid leukaemia presenting as recurrent generalized urticaria in infancy
European Journal of Pediatrics (2008)